Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 4 (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Pharmaceutical Regulatory System for Vaccine Approval: A Comparative Study of Indian, Australian and Japanese Systems

T. Sathish T [1], N. Jawahar N [2], Kari V V S Narayana Reddy[3]

[1]Department of Pharmaceutical Regulator Affairs, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India
ORCID ID:0000-0002-1971-0331

[2]Department of Pharmaceutical Regulator Affairs, JSS College Of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India
ORCID ID:0000-0003-0737-1237

[3]Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Nilgiris, Tamil Nadu, India.
ORCID ID:0000-0003-2057-3243

***Corresponding Author:**
T Sathish

Cite this paper as: T. Sathish T, N. Jawahar N, Kari V V S Narayana Reddy, (2025) Pharmaceutical Regulatory System for Vaccine Approval: A Comparative Study of Indian, Australian and Japanese Systems. *Journal of Neonatal Surgery*, 14 (4), 262-276.

ABSTRACT

Vaccine regulation is significantly different among Asia-Pacific countries, with each country taking on a unique approach based on its capabilities and needs. This study explores the regulatory frameworks for vaccine development and approval in India, Australia, and Japan, focusing on their methodologies and potential for international harmonization. Four key aspects will be analyzed: approval processes, clinical trial requirements, quality control standards, and post-marketing surveillance systems, especially GMP standards and pharmacovigilance requirements under the impact of the COVID-19 pandemic.The results present clear, distinguishing characteristics of the different countries under study: India developed a pragmatic system focused on global manufacturing capabilities, while Australia maintained robust processes with high international harmonization. In Japan, although there exists a strict approval pathway, international cooperation increased over time. Regulatory changes were catalyzed by the COVID-19 pandemic, especially in expedited review processes and international collaboration.Country-specific adjustments to convergence in standards continue to be called for. Major cited challenges include unevenness in terms of resource distribution, differences in technological capabilities and issues concerning coordination among nations. Vaccine regulation may well find its shape in reaction to innovation with digital technology, advanced analytics, and stronger international cooperation and is likely to demand careful attention to local conditions.This gives valuable insights into the regulation of vaccines by the authorities, pharmaceutical firms, and policymakers, thus working in harmony to strengthen health security. In essence, these give scope for both opportunities presented by digital transformation and international cooperation, with emphasis on local contextualization for implementation.

Keywords: *Vaccine Regulation, Regulatory Frameworks, Clinical Trials,International Harmonization, Pharmacovigilance, Quality Control Standards, Regulatory Convergence*

1. INTRODUCTION

Vac. Vaccines are the greatest public health success stories in medical history because they have prevented millions of deaths and disabilities through immunization against infectious diseases[1]. In this regard, strict regulatory oversight is required in the development, manufacture, and distribution of vaccines to ensure their safety, efficacy, and quality[2]. This regulation framework is essentially the core foundation of public health protection-creating standard processes for evaluating, approving, and monitoring vaccines after their sale[3]. The COVID-19 pandemic that has recently swept the world highlights the importance of regulatory systems, including the need for high demanding standards while remaining adaptive in public health emergencies[4].

A comparison of the various regulatory frameworks in India, Australia, and Japan can allow appreciationof the different approaches to vaccine regulation in the Asia-Pacific region[5]. Every country has a stage of economic development, with a distinct variation in health systems, and maturity levels of different regulatory agencies[6]. Taking one of the most important

vaccine manufacturing companies, based on this planet - being situated in India means their regulatory system would have taken ages to get what best satisfies its requirements to international norms[7]. Australia, the case being very highly sophisticated, happens to fall well within a typical regulatory system followed by the West; whereas, Japan becomes technologically innovative while in a depth regulation conservative scenario. The two countries reflect the importance of knowing how to understand each other's different regulatory structures to face common challenges under distinct characteristics rooted in local healthcare needs, culture, and history[8].

This is to give a rather detailed analysis of regulatory pathways for vaccine development in the three countries on best practices, challenges, and opportunities for convergence[9]. Comparators and differences in approach between the three countries and across the three countries form part of the overall Asia-Pacific regulatory convergence dialogue[5]. The objectives of the study are as follows: measuring the effectiveness and efficiency of the regulatory processes in place in each country; analyzing their adaptability to new emerging technologies and public health emergencies, and identifying points for improvement and international cooperation[10]. Understanding these regulatory frameworks will be important to all those involved in developing vaccines-whether pharmaceutical, regulatory, health service providers, and policy-makers, all working toward a higher ideal of greater global health security[11].

How Vaccines Work

Vaccines are engineered to condition a human immune system to learn the germs, viruses, or bacteria, that are dangerous to its health, and how it can fight back such diseases. They generally make use of weakened, inactivated, or other parts of germs, like proteins. It elicits an immune response from the body by producing antibodies and activating the immune cells to prepare the body for a swift defence if it were exposed to a real pathogen in the future, thus preventing or reducing its severity[12, 2].

Vaccine Development

Developing vaccines remains a very rigorous multi-phased process that guarantees safe, effective, and qualitative outcomes[13]. The first approach involves identifying the target pathogen and researching its nature and behavior. Pre-clinical testing is in the laboratory and animal models for safety and immune responses[14]. Those candidates that move on from this phase undertake clinical trials, which are approached in three stages:

Phase 1: Safety and dose testing in a few healthy volunteers.

Phase 2: Hundreds of participants are involved to test for safety and immune response.

Phase 3: Thousands of participants are involved to establish the effectiveness and rare side effects.

If successful, it undergoes regulatory review and approval, including postapproval monitoring on long-term safety and efficacy. In recent years, technologies such as mRNA and viral vectors have catapulted vaccine development into lightning speed, bestepitomized by the swiftness of responseof the vaccines on COVID-19[15,16].



Figure 1: How vaccines work (https://www.clinicbarcelona.org/en/assistance/be-healthy/vaccine-1/how-do-vaccines-work)

2. VACCINE DEVELOPMENT PROCESS

This stage starts with the Preclinical phase, which is the foundational period of 2-4 years. Here, scientists identify and select suitable antigens that might trigger the desired immune response. This phase is very intense in laboratory testing, involving cell culture studies and comprehensive animal trials to assess safety parameters and immune responses. Meanwhile, the researchers have started developing and optimizing manufacturing processes for eventual scalability[14].

After successful preclinical testing, the process progresses into Phase I clinical trials. These are usually short and last between 6 and 12 months. During this first human test stage, a small number of 20-100 healthy adult volunteers are used. At this stage, the main aim is to determine the safety profile in humans and assess the vaccine's ability to induce immunity. Safety data are collected based on adverse reactions or side effects in participants[17].

Phase II is relatively bigger, normally taking between 1 to 2 years to be completed. Here, hundreds of people are put on trial so that one may determine the dosage of maximum efficacy but safety is also ensured. The researcher will attempt to confirm the presence of desired immune responses by testing it on more people. This phase shall also describe and analyze how many side effects come up more frequently because more people take part[13].

The most comprehensive testing on humans is in Phase III trials. It usually takes 2 to 4 years to achieve this and involves thousands of people in different demographics and different geographic locations. The first main goals are to establish without doubt the vaccine's effectiveness in preventing the disease in question and to look for those rare adverse effects that would not appear in smaller-scale earlier tests. This is when the maximum amount of data regarding vaccine efficacy and safety profile are available[16].

The final stage is the regulatory approval and scaling of production. At this stage, regulatory bodies carry out thorough reviews of all data that has been gathered during the previous stages. Upon receiving the approval, manufacturing activities are scaled up with quality control measures. This stage encompasses the design of distribution plans and the establishmentof a post-launch surveillance system that is productive to monitor the performance as well as the safety record of the vaccine in reality. This surveillance continues unabated during the entire tenure of the vaccine's being in active use among the population with an open eye to discern any long-term effects, which may arise rarely[18].





Figure 2: vaccine development process

3. INDIVIDUAL COUNTRY ANALYSIS SECTION

India: The path of vaccine regulation in India goes back to the Drugs and Cosmetics Act of 1940 which laid down the framework for regulation of pharmaceuticals. It was a sea change, however, with the advent of India as a global player in vaccine manufacturing in the late 20th century. The establishment of CDSCO marked another important landmark in the enhancement of the regulatory framework. Under the leadership of the Drug Controller General of India, or DCGI, the CDSCO acts as the nodal regulatory authority to authorize new vaccines, regulate clinical trials, and monitor their quality. The organization coordinates state-level authorities to implement regulatory policies efficiently[7,19].

The clinical trials undertaken in India follow a four-stage structure that is identical to the international standards. In this, Phase I would contain 20-100 volunteer healthy subjects for an initial safety test, Phase II would possibly contain 100-300 subjects, and Phase III may contain more significant populations, such as 1000-3000 patients to be confirmed effective. Moreover, Phase IV includes post-marketing surveillance. These have further made the requirements more streamlined in the New Drugs and Clinical Trials Rules, 2019. Timelines for regulatory decisions and the protection of participants involved in trials have also been made stringent. Schedule M of the Drugs and Cosmetics Rules has made adherence to the GMP mandatory for all manufacturing facilities as set up specifically for the Indian context but in consonance with the WHO GMP guidelines[20,21].

India has followed up with a sound Pharmacovigilance Program well-coordinated by the Indian Pharmacopoeia Commission; in addition, it established and follows a system called the AEFI monitoring network and maintains a network of surveillance centres for surveillance all over the nation. As a result of the existing COVID-19 pandemic, an expedited emergency use authorization protocol was developed, whereby vaccine candidates could be reviewed even more quickly than before, but safety and efficacy would not be sacrificed at any cost[22,23].

Figure 3: Registration process for India



Figure 4: The regulatory approval process for India

Australia: Therapeutic Goods Act 1989 forms the foundation of the regulatory framework of Australia for vaccines, building a broad-based system of control over therapeutic products. The TGA is one of the world's most renowned regulatory agencies with high scientific scrutiny processes and risk-based approaches. The scope includes pre-market evaluation as well as post-market surveillance and is part of a framework that puts forth the need for scientific soundness and public safety together[24].

Clinical trials in Australia are streamlined through the Clinical Trial Notification (CTN) or Clinical Trial Exemption (CTX) schemes. These approaches allow for quicker initiation of trials while still maintaining robust oversight. Under the CTN scheme, ethics committee approval is followed by TGA notification to begin the trial, whereas, under the CTX scheme, a

detailed review by TGA is required before the trial can begin. The GMP requirements of Australia are almost similar to those requirements of international standards, including PIC/S, so the manufacturing facilities have to meet tough quality requirements[25].

The TGA also maintains a comprehensive post-market surveillance system, which monitors adverse events through the DAEN. Specific protocols have been established for provisional approval pathways, such that in an emergency, temporary registration of vaccines is allowed based on preliminary clinical data, with the need for continued submission of complete efficacy and safety data[26].



Figure 5: Registration process of Australia



Figure 6: Regulatory approval process for Australia

Japan: Events such as the vaccine-related disasters of the 1970s have moulded the regulatory system for vaccines in Japan into one of the strictest in the world. The Pharmaceuticals and Medical Devices Agency (PMDA), established in 2004, is a subordinate agency to the Ministry of Health, Labour and Welfare (MHLW) and exercises overall regulatory oversight. An extensive pre-consultation process and detailed technical requirements are hallmarks of the Japanese regulatory culture[27].

Clinical trials in Japan have to adhere to certain guidelines as stipulated by the Pharmaceutical and Medical Device Act. This

is usually a procedure of considerable consultation with the PMDA before commencing a trial, which usually proceeds on a phased schedule that is similar to standards set in other countries, but includes some requirements applicable locally. Japanese GMPs, although harmonized with international guidelines, present additional quality control and documentation requirements. The country has a specific requirement for domestic clinical data, though the acceptance of foreign clinical trial data has recently increased due to reforms[28].

Japan has a pretty good post-marketing surveillance system. Manufacturers have to carry out particular post-marketing safety studies, called GPSP, or Good Post-marketing Study Practice, and also file periodic safety updates. There is also mandatory reporting of adverse events through the Japanese Adverse Drug Event Report database, JADER. Japan, to deal with the COVID-19 pandemic, came up with emergency approval pathways under Article 14-3 of the Pharmaceutical Affairs Act, where vaccines could be reviewed expediently, keeping core safety requirements intact[8].



Figure 7: The regulatory approval process for Japan



Figure 8 Registration process in Japan

4. COMPARATIVE ANALYSIS OF THE REGULATORY FRAMEWORKS ACROSS INDIA, AUSTRALIA, AND JAPAN

Regulatory Pathway Timelines: The three countries vary significantly in their review timelines. India typically completes standard vaccine reviews within 180-270 days, but accelerated reviews are possible within 120 days. The TGA in Australia operates under a 255 working-day timeline for standard reviews, and priority review pathways can complete the review within 150 days. The longest review period, on average, belongs to Japan's PMDA, which, in addition to its broad pre-consultation requirements and elaborate technical reviews, usually requires up to 12-18 months. Yet, expedited pathways have been created by all three countries for the use of vaccines that treat pressing public health needs. Emergency protocols allow for reviews within 60-90 days[17,29].



Documentation Requirements: A comparative evaluation shows different jurisdictions placing a different level of emphasis on documentation. India's CDSCO mandates extensive Chemistry, Manufacturing, and Controls (CMC) information along with local clinical trial information, though the requirement for bridging studies may be exempted in cases where earlier approvals have been received in regulated countries. Australia's TGA accepts common technical documents (CTD) format and, in general, accepts data from other ICH member countries and has fewer country-specific requirements for documentation. Japan maintains the most stringent documentation requirements, often demanding Japan-specific CMC data and local clinical studies, though recent reforms have increased flexibility in accepting foreign data[30].



Quality Control Standards: Quality control standards reveal significant convergence, reflecting efforts toward international harmonization. All three countries follow the WHO GMP guidelines, but with local adaptations, however. India's Schedule M requirements include additional specifications concerning tropical climate conditions and local manufacturing practices. Australian standards are very close to the EU GMP requirement due to PIC/S membership. Japan's standards surpass international requirements in several respects, especially in sterility assurance and environmental monitoring. The most significant difference is in the stability testing requirements. India requires specific studies under Zone IVb conditions, whereas Australia and Japan follow ICH stability guidelines[31,32].



Clinical Trial Requirements: The clinical trial landscape reveals that there are differences in study design and data acceptance. India demands phase-wise clinical trials, though it is possible to exempt some phases from the vaccines approved in well-regulated countries. India demands certain ethnic representation in the trial as well as post-marketing studies. Australia's CTN/CTX scheme has the flexibility of initiating a trial while being under scrutiny. Japan traditionally required full domestic clinical trials but is now appearing to be much more welcoming of foreign data through the efforts of international regulatory convergence. Sample size requirements also differ: India generally will accept less extensive safety databases for licensure than do Australia and Japan, where robust plans for post-marketing surveillance are in place[33,34].



Post-marketing Surveillance: The post-marketing surveillance systems have varying emphasis on active versus passive surveillance:

India:

• Nationwide AEFI surveillance network

• Mandatory periodic safety update reports (PSURs) every six months for two years

• Active surveillance through sentinel sites

• Risk management plans for new vaccines [21]

Australia:

• AusVaxSafety active surveillance system

• Real-time monitoring through SMS-based feedback

• Integration with international databases

• Risk management plans according to EU [35]

Japan:

• Most intense post-marketing requirements

• Mandatory early post-marketing phase vigilance (EPPV) for six months

• Patient registry requirements for new vaccines

• Regular safety periodic reports with unique Japanese formatting [36,8]

5. CHALLENGES AND OPPORTUNITIES IN VACCINE REGULATORY FRAMEWORKS:

Resources, there are resource allocation variations around the three countries: While resources are somewhat constrained across a large pharmaceutical sector to fill adequate staffing for regulating processes in India, it seems in other ways to also promote innovative solutions such as 'digital transformation' or partnership between public and private stakeholders. Australia's TGA functions with more efficient resource management but is less able to retain expertise in all therapeutic areas due to its smaller population base. Japan's PMDA is well-resourced, but bureaucratic processes are so complex that they create inefficiencies, although this ensures that the review process can be quite thorough [6].

Technical capabilities:The technical landscape has a good and weak strength and weakness profile. India emerged as the global vaccine manufacturing hub, possessing relatively good technical capabilities in the production area but still lagging in advanced analytical techniques and specialized testing facilities. Programs have been initiated in the country to upgrade testing laboratories and technical expertise. Australia is showing leading capabilities in assessing novel vaccine technologies but has weaknesses in domestic manufacturing capability. Japan has a strong technological capacity with high-quality control but, on occasion, it has shown lags in embracing new technologies through conservative approaches in its regulation [1].

Technical Issues:

There are regions with little capability in advanced analytical testing.

Experts in the field are needed for novel vaccine platforms like mRNA and viral vectors

Testing facilities with older infrastructures

•Specialized storage and cold chain validation requirements

•Growing demand for real-time release testing capabilities [37]

International Coordination: Global vaccine development has brought both opportunities and challenges in international coordination. India has been able to advance towards international standards without sacrificing sovereignty in regulatory decisions. The country is an active participant in WHO initiatives and maintains bilateral agreements with many other regulatory authorities. Australia has successfully integrated into the international regulatory networks, especially through membership to PIC/S and ICH, providing mutual recognition agreements. Japan has enhanced international cooperation by attending regulatory meetings with PMDA with maintaining very high standards that cater to local needs.Coordination Efforts [10]

• Harmonization of GMP inspection procedures

• Information sharing on safety signals

• Joint review programs for pandemic vaccines

• Regulatory exchanges to build capacity

• Development of common guidelines on new technologies [5]

Emergency Response Preparedness: COVID-19 exposed both strengths and weaknesses of emergency response:

India:

• Rapid adaptation to protocols, massive manufacturing capacities

• Challenges: Need for stronger data management systems, standardization of emergency procedures

• Opportunities: Development of dedicated emergency review pathways, enhancement of digital infrastructure [19]

Australia:

• Strengths: Strong framework of emergency use authorization, strong pharmacovigilance

• Challenges: Limited domestic manufacturing capacity for emergency response

• Opportunities: Enhancement of regional cooperation, strengthening of local production capabilities [35,25]

Japan:

• Strengths: Systematic approach to emergency approvals, strong quality control

• Challenges: Time-consuming decision-making processes even in emergencies

• Opportunities: Streamlining of emergency procedures, increased flexibility in data requirements [38,39]

The future of vaccine regulation is at the crossroads of significant transformation through technological advancement and increased international cooperation. Technologically, application screening will be revolutionized by artificial intelligence and supply chain management will become transparent and traceable using blockchain technology. Real-time surveillance

systems and comprehensive digital platforms for regulatory submissions will streamline the whole regulatory process, thereby making it more efficient and transparent [40,41].

Capacity building would take place through innovative approaches in the areas of knowledge sharing and expertise development that reinforce stronger regulatory frameworks. It will involve creating joint training programs as well as shared assessment tools for the standardization of all regional regulatory practices. Programs of expert exchange, along with regional centers of excellence, would develop to facilitate transferring knowledge and building up of the capability of regulatory actions which will be a huge bonanza for emerging markets and developing regulatory systems [26,42].

Regulatory innovation is an important feature of future development that includes the introduction of adaptive licensing pathways able to respond more flexibly than before to emerging public health needs. It introduces rolling reviews to facilitate the acceleration of evaluation in a manner that does not compromise safety standards; employs risk-based approaches to maximize resource use; and adopts emergency protocols harmonized toward a single response to global health threats. These innovations will make the regulatory systems more efficient and responsive while keeping the standards for safety and efficacy high [43,44].

Global cooperation will thus be the decisive factor of the future regulatory regime, through the establishment of strong networks of information sharing and joint programs of inspection. Mutual recognition agreements will remove the redundancy of regulations, hence speeding up vaccine access across markets. In addition, collaborative research initiatives are sources of innovation and strengthen the scientific basis of regulatory decision-making. This will lead to better-coordinated and more efficient regulatory processes across the globe, thereby enhancing access to safe and effective vaccines globally [45,46].

All these together point toward a more integrated, efficient, and technologically advanced regulatory environment that can better serve global public health needs while keeping the highest standards of vaccine safety and quality. Their success will depend on continued commitment to international cooperation and sustained investment in regulatory science and infrastructure [47].

Table 1: Indian Regulatory Updates During the COVID-19 Pandemic

Regulatory Update	**Description**	**Key Points**	**Impact on Vaccine Development**
Rapid-track Approvals Process	Regulatory streams for COVID-19 vaccine development and approval	Quicken the clinical trials by relaxing the timeline for data submission. Emergency use authorizations (EUA) are issued.	Reduced the market timeline for vaccines, and quicker response to the pandemic.[22]
Deregulation of Regulatory Rules	Temporary removal of certain regulatory rules that ease vaccine development and manufacturing.	Relaxation in the protocols of clinical trial, data submission, and manufacturingprocess	Less paperwork and shorter turnaround time in vaccine development and production.[19]
More Cooperation	Greater cooperation between the regulatory agencies, researchers, and the industry.	Scientific work groups were done in conjunction with other information-sharingand coordinated regulatory decisions.	Better communications and coordination therefore improve the faster and more effective vaccine development process.[5]
Prioritization of COVID-19 vaccine development	Resource allocation and attention towards the COVID-19 vaccine development.	Funding allocation, technical support, and research as well as approval of vaccine applications.	Fast-developing vaccines.[48]
Public-Private Partnerships	Collaboration between Government, Academia as well as Industry to advance the development and also the production of vaccines.	Coordinated research activities, financial provision as well as technologies.	Relying on collective experience as well as resources, built it much sooner as well as manufacturing capacities were boosted.[49]

6. FUTURE DIRECTIONS IN VACCINE REGULATORY FRAMEWORKS:

Trends arising in regulatory science: Technological advancement and global health needs dictate the fast-changing nature of regulatory science. Artificial Intelligence and Machine Learning are more and more being introduced into regulatory decision-making processes in pharmacovigilance and safety signal detection. The real-world evidence is increasing, and regulatory authorities that initiate developing frameworks are allowing RWE integration at both pre- andpost-approval stages. Advanced therapy medicinal products and personalized vaccines create regulatory boundaries and call for more flexible and agile approaches. Already digital health technologies, and new clinical trial designs, such as decentralized trials, are re-writing the classic paradigms of the traditional regulatory one [50].

Emerging Trends

1. Implementation of AI/ML in the regulatory process

2. Integration of real-world evidence

3. Sophisticated analytics for advanced safety monitoring

4. Novel designs for clinical trials

5. Platform technologies for rapid development of vaccines [6]

Improvement Areas: Each country has different areas that need to be improved upon in the system. India should upgrade its IT structure about regulation and also require improvement in coordination between the centre and states. Australia would improve its domestic manufacturing ability and acquire specialized knowledge of the newly evolved technologies. The review processes need to be simplified and accept global data, Japan needs to improve its regulatory system. All the countries are similar in the following aspects [31].

1. Improving Regulatory Process

Streamlining application procedure

•Cut review timelines

•More transparency in the decision

• Risk-based approach [51]

2.Technical Capability Building:

•Building expertise in the new technology

•Strengthening of laboratory facilities

•Up gradation of data analysis capability

• Building up the pharmacovigilance system [18]

The future of vaccine regulation will be based on global harmonization but still have country-specific requirements. This will include standardization of electronic submissions, manufacturing practices, safety reporting, and quality control across the nations. Increased cooperation is evident through joint reviews and unified emergency procedures, while standardized frameworks are being established for clinical trials, stability testing, and pharmacovigilance.[45].

The COVID-19 pandemic has catalyzed transformative changes in the approach to regulation that would provide immediate and lasting impacts. This short-term impact is quickening the review processes, encouraging international cooperation, introducingregulation flexibility, and strengthening the surveillance systems. In the long term, the heritage includes permanent emergency response protocols, enhanced cross-border coordination, streamlined data-sharing mechanisms, and more robust supply chain management systems [31].

This has led the field to progress on multiple fronts: real-time monitoring and automated screening are made possible by digital systems, and data sharing and coordinating efforts globally through networks are possible. Scientific innovations in this regard include advanced modelling and standardized protocols. In terms of risk management, sophisticated benefit-risk assessments have evolved into proactive safety monitoring [15].

In the future, reliance on real-time data analytics will change the nature of the regulatory environment from a reactive approach to a proactive one. Regulatory frameworks will be more flexible and responsive, with stronger coordination mechanisms at the global level and better preparedness in emergencies. This change represents a further understanding that regulation of vaccines will necessitate local and international expertise with a healthy balance in favour of the need to provide swift responses in public health crises [40].

This implies that all stakeholders the regulatory authority to the manufacturer and the public health organisation to come together with a sustained commitment. The outcome will be seen through the balance between pressure for standardization

and the capacity to respond to local priorities and emerging issues. Fundamentally, this is not about technical change but a change in the way vaccine regulation thinks and does things worldwide [45].

Conclusion

The regulatory frameworks of vaccines in India, Australia, and Japan are different since divergence has been shaped by differences in healthcare needs, cultural contexts, and historical experiences. While India has pragmatic flexibility, Australia stands as one example with robust international harmonization, and Japan shows rigid approval pathways with gradual collaboration around the world.

Although there is convergence on GMP standards, clinical requirements and post-marketing surveillance, review timelines, documentation requirements, and local clinical data needs diverge. The COVID-19 pandemic accelerates regulatory evolutions that come with reviews on expediting timelines and more significant international cooperation that is bound to find the need for regulatory agility and more global collaborations at a call of time.

The future of regulation is going to be characterized by the three dimensions of digital innovation, advanced analytics, and strengthened global cooperation. Standard harmonization, simplified approvals, better surveillance systems, and adaptive frameworks for health threats are to be developed in the identified priority areas. The search for a balance between global coordination and local needs would result in success, facilitated by investments in regulatory science and capacity building.

Conflict of Interest: No

REFERENCES

[1] Moradpour J, Chit A, Besada-Lombana S, Grootendorst P. Overview of the global vaccine ecosystem. Expert Rev Vaccines. 2023 Jan-Dec;22(1):749-763. doi: 10.1080/14760584.2023.2250433. PMID: 37608523.

[2] Plitnick LM. Global regulatory guidelines for vaccines. InNonclinical development of novel biologics, biosimilars, vaccines and specialty biologics 2013 Jan 1 (pp. 225-241). Academic Press.

[3] Baylor NW. Role of the national regulatory authority for vaccines. International Journal of Health Governance. 2017 Sep 4;22(3):128-37.

[4] Nachlis H, Thomson K. Emergency Regulatory Procedures, Pharmaceutical Regulatory Politics, and the Political Economy of Vaccine Regulation in the COVID-19 Pandemic. J Health Polit Policy Law. 2024 Feb 1;49(1):73-98. doi: 10.1215/03616878-10910278. PMID: 37522337.

[5] Lacey S, Mitchell AD. Regulatory Cooperation for Vaccines: The Asia-Pacific and Beyond. Asian International Studies Review. 2023 Apr 26;24(1):74-102.

[6] Shi J, Chen X, Hu H, Ung COL. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Front Public Health. 2023 May 4;11:1172557. doi: 10.3389/fpubh.2023.1172557. PMID: 37213606; PMCID: PMC10192700.

[7] Salalli R, Dange JR, Dhiman S, Sharma T. Vaccines development in India: advances, regulation, and challenges. Clin Exp Vaccine Res. 2023 Jul;12(3):193-208. doi: 10.7774/cevr.2023.12.3.193. Epub 2023 Jul 31. PMID: 37599804; PMCID: PMC10435768.

[8] Sakurai A, Kanzaki S, Honda F. Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union. Clin Pharmacol Ther. 2023 May;113(5):960-962. doi: 10.1002/cpt.2788. Epub 2022 Nov 20. PMID: 36404404.

[9] Lacey S, Mitchell AD. Regulatory Cooperation in Vaccines in Asia-Pacific Region. Available at SSRN 4217244. 2022 Jun 17.

[10] Mahoney R, Hotez PJ, Bottazzi ME. Global regulatory reforms to promote equitable vaccine access in the next pandemic. PLOS Glob Public Health. 2023 Oct 18;3(10):e0002482. doi: 10.1371/journal.pgph.0002482. PMID: 37851688; PMCID: PMC10584090.

[11] Kumar N, Darshan M, Islam F. Ensuring global health: a comprehensive review of vaccine regulation with a focus on the Indian perspective. International Journal of Community Medicine and Public Health. 2024 Feb;11[2]:989.

[12] Tizard, Ian R.. “Production, assessment, and regulation of vaccines.” (2021).

[13] Baylor NW. The Regulatory Evaluation of Vaccines for Human Use. Methods Mol Biol. 2016;1404:773-787. doi: 10.1007/978-1-4939-3389-1_51. PMID: 27076337.

[14] Gorenkov DV, Komarovskaya EI, Soldatov AA, Avdeeva ZhI BV. Current regulatory requirements for non-clinical evaluation of prophylactic vaccines. Biological Products. Prevention, Diagnosis, Treatment. 2023;23(1):7-25.

[15] Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, Severino P, Priefer R,

Prajapati BG, Maheshwari R. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024 May;180:1-17. doi: 10.1016/j.actbio.2024.04.010. Epub 2024 Apr 10. PMID: 38604468.

[16] Särnefält A, Eardley-Patel R, Magini D, Sonje V, Guzzi A, Hesselink R, Scotney M, Lazdins A, Chambard V, Vinnemeier C, Kromann I. A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI's CMC Framework. PDA J Pharm Sci Technol. 2024 Oct 22;78(5):613-623. doi: 10.5731/pdajpst.2023.012912. PMID: 39054065.

[17] Narasimhan J, Maanvizhi S. Regulatory approval pathway for COVID-19 vaccine in USA, Europe and India. Ann Med Surg (Lond). 2023 Mar 2;85(4):860-867. doi: 10.1097/MS9.0000000000000000. PMID: 37113820; PMCID: PMC10129106.

[18] Gestakovska A, Moskova B, Sterjev Z, Grozdanova A, Suturkova L, Nestorovska AK, Naumovska Z. The legal and regulatory framework for vaccine pharmacovigilance.

[19] Pathak D, Philo Magdalene A. COVID-19 Vaccine Development and Administration in India. InHealth Dimensions of COVID-19 in India and Beyond 2022 Apr 9 (pp. 129-154). Singapore: Springer Nature Singapore.

[20] PONNAPALLI, RAMYA & DIVYA, MANTENA & Raju, K. & Nori, Lakshmi. (2023). REGULATORY FRAMEWORK: VACCINE DEVELOPMENT IN US, INDIA AND EU. International Journal of Applied Pharmaceutics. 63-71. 10.22159/ijap.2023v15i2.46723.

[21] Gogtay NJ, Dhingra MS, Yadav A, Chandwani H. Vaccine policy, regulations and safety in India. International Journal of Risk & Safety in Medicine. 2009 Jan 1;21(1-2):23-30.

[22] Dinda AK, Tripathi SK, John B. Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy. Indian J Med Res. 2020 Jul & Aug;152(1 & 2):156-163. doi: 10.4103/ijmr.IJMR_3640_20. PMID: 32952146; PMCID: PMC7853266.

[23] Grundy J. Country-level governance of global health initiatives: an evaluation of immunization coordination mechanisms in five countries of Asia. Health Policy Plan. 2010 May;25(3):186-96. doi: 10.1093/heapol/czp047. Epub 2009 Nov 19. PMID: 19926659.

[24] Shinde AA, Gurav AS, Chaudhari BP, Redasani VK. A Review on Pharmaceutical Regulatory Authority of India, USA, UK, Australia. Asian Journal of Research in Pharmaceutical Science. 2024 Sep 1;14(3).

[25] Gowthami KR, Balamuralidhara V., Maanvizhi S, Deeksha KS, Bairi MU. Regulatory Requirements and Approval Process for Medical Devices in Japan, Australia and Brazil. ACMMR-V8 [Internet]. 2023 Dec. 15 [cited 2024 Dec. 26];:127-53. Available from: https://stm.bookpi.org/ACMMR-V8/article/view/12792

[26] Khadem Broojerdi A, Alfonso C, Ostad Ali Dehaghi R, Refaat M, Sillo HB. Worldwide Assessment of Low- and Middle-Income Countries' Regulatory Preparedness to Approve Medical Products During Public Health Emergencies. Front Med (Lausanne). 2021 Aug 13;8:722872. doi: 10.3389/fmed.2021.722872. PMID: 34485350; PMCID: PMC8414408.

[27] Nagai S, Ozawa K. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. Curr Gene Ther. 2017;17(1):17-28. doi: 10.2174/1566523217666170406123231. PMID: 28382858.

[28] T R P, Kumar S, R K. A Comparative Analysis of the Regulatory Framework and Collaborative Environment for Pediatric Medical Device Development in Japan and the United States: Identifying Challenges, Support Mechanisms, and Emerging Opportunities. Cureus. 2024 Sep 3;16(9):e68583. doi: 10.7759/cureus.68583. PMID: 39371858; PMCID: PMC11452317.

[29] Jones PG, Cowan G, Gravendyck M, Nagata T, Robinson S, Waits M. Regulatory requirements for vaccine authorisation. Rev Sci Tech. 2007 Aug;26[2]:379-93. PMID: 17892159.

[30] Lodha S, Patel H, Joshi S, Kalyankar G, Mishra A. Regulatory requirements of regulated market. InRegulatory Affairs in the Pharmaceutical Industry 2022 Jan 1 (pp. 113-161). Academic Press.

[31] Hock SC, Pheh A, Sachdeva V, Wah CL. Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines. GaBI Journal. 2022;11(1):13-24.

[32] Moore HC, Cannon JW, Kaslow DC, Lamagni T, Bowen AC, Miller KM, Cherian T, Carapetis J, Van Beneden C. A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases. Clin Infect Dis. 2022 Sep 30;75(7):1245-1254. doi: 10.1093/cid/ciac291. PMID: 35438130; PMCID: PMC9525082.

[33] Nishioka Sde A. Cooperation between regulatory authorities from developing countries in the evaluation of vaccine clinical trials. Cad Saude Publica. 2008 Sep;24(9):2191-2. doi: 10.1590/s0102-311x2008000900026.

PMID: 18813696.

[34] Radhakrishna SD, Shriram RG, Khaleeli S, Dawar P, Kottayi MC, Dubey A. Comparison and Compilation of the vaccine Approval process of the United States of America and the European union: a Road Map for the emerging and developing countries in COVID-19 crisis. Indian J of Pharmaceutical Education and Research. 2021 Apr 1;55(2s):s353-63.

[35] Jose J, Pai S. Comparison of regulatory framework of clinical trial with genetically modified organism-containing vaccines in the Europe, Australia, and Switzerland. Clin Exp Vaccine Res. 2021 May;10[2]:93-105. doi: 10.7774/cevr.2021.10.2.93. Epub 2021 May 31. PMID: 34222122; PMCID: PMC8217574.

[36] Ingle D, Bhavsar R, Pawar J, Patil A, Nerkar P. Overview oi vaccine regulations in european union and Japan. International Journal Of Drug Regulatory Affairs. 2022;10(1):14-22.

[37] Sutkowski EM, Gruber MF. Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccines. InImmunopotentiators in Modern Vaccines 2006 Jan 1 (pp. 343-359). Academic Press.

[38] Ujiie M. Establishment of an emergency regulatory approval system in Japan in response to the COVID-19 pandemic and challenges in developing domestically produced vaccines. Glob Health Med. 2022 Apr 30;4[2]:144-145. doi: 10.35772/ghm.2022.01023. PMID: 35586772; PMCID: PMC9066468.

[39] Kondo K, Taguchi C. Japanese Regulatory Framework and Approach for Genome-edited Foods Based on Latest Scientific Findings. Food Saf (Tokyo). 2022 Dec 23;10(4):113-128. doi: 10.14252/foodsafetyfscj.D-21-00016. PMID: 36619008; PMCID: PMC9789915.

[40] Honig P, Zhang L. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation. Clin Pharmacol Ther. 2019 Apr;105(4):778-781. doi: 10.1002/cpt.1367. PMID: 30883715.

[41] Dellepiane N, Akanmori BD, Gairola S, Jadhav SS, Parker C, Rodriguez C, Srivastava S. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S428-33. doi: 10.1093/cid/civ491. PMID: 26553671; PMCID: PMC4639481.

[42] Milstien J, Belgharbi L. Regulatory pathways for vaccines for developing countries. Bull World Health Organ. 2004 Feb;82[2]:128-33. Epub 2004 Mar 16. Erratum in: Bull World Health Organ. 2004 Nov;82(11):881. PMID: 15042235; PMCID: PMC2585911.

[43] Cox MM, Onraedt A. Innovations in vaccine development: can regulatory authorities keep up? Expert Rev Vaccines. 2012 Oct;11(10):1171-3. doi: 10.1586/erv.12.96. PMID: 23176649.

[44] Jones C. Glycoconjugate Vaccines: The Regulatory Framework. Methods Mol Biol. 2015;1331:229-51. doi: 10.1007/978-1-4939-2874-3_14. PMID: 26169744.

[45] Dellepiane N, Pagliusi S, Akut P, Comellas S, De Clercq N, Ghadge S, Gastineau T, McGoldrick M, Nurnaeni I, Scheppler L; Regulatory Experts Working Group. Alignment in post-approval changes (PAC) guidelines in emerging countries may increase timely access to vaccines: An illustrative assessment by manufacturers. Vaccine X. 2020 Aug 25;6:100075. doi: 10.1016/j.jvacx.2020.100075. PMID: 32995745; PMCID: PMC7516132.

[46] Gronvall GK, Borio LL. Removing barriers to global pandemic influenza vaccination. Biosecur Bioterror. 2006;4[2]:168-75. doi: 10.1089/bsp.2006.4.168. PMID: 16792484.

[47] Hausdorff WP, Madhi SA, Kang G, Kaboré L, Tufet Bayona M, Giersing BK. Facilitating the development of urgently required combination vaccines. Lancet Glob Health. 2024 Jun;12(6):e1059-e1067. doi: 10.1016/S2214-109X(24)00092-5. Epub 2024 Apr 15. Erratum in: Lancet Glob Health. 2024 Apr 25:S2214-109X(24)00184-0. doi: 10.1016/S2214-109X(24)00184-0. PMID: 38636529; PMCID: PMC11099297.

[48] Lalani B, Sobti S. Adopting a logical framework model to help achieve a balanced and healthy vaccine R&D portfolio. Wellcome Open Res. 2019 Jul 1;4:64. doi: 10.12688/wellcomeopenres.15168.2. PMID: 31346552; PMCID: PMC6625608.

[49] Marandi V, Tabatabaeian SH, Jafari P, Azarnoosh M. Challenge-based approaches for policy-making in vaccine development and production.

[50] Patel M, Miller MA. Impact of regulatory science on global public health. Kaohsiung J Med Sci. 2012 Jul;28(7 Suppl):S5-9. doi: 10.1016/j.kjms.2012.05.003. Epub 2012 Jul 10. PMID: 22871603.

[51] Breckenridge A, Feldschreiber P, Gregor S, Raine J, Mulcahy LA. Evolution of regulatory frameworks. Nat Rev Drug Discov. 2011 Jan;10(1):3-4. doi: 10.1038/nrd3348. PMID: 21193854.